MedTrace Logo

Resistant Arterial Hypertension Cohort Study

NCT01083017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 74

Last updated 2018-10-30

No results posted yet for this study

Summary

The purpose of this study is to investigate the epidemiology of resistant hypertension, evaluate the efficacy and feasibility of a standardized drug treatment regimen (including the randomization of two doses of the diuretic used - chlorthalidone), study two interventions in the group of patients that is non-compliant, and study environmental and genetic variables of individuals with resistant hypertension in a family design.

Conditions

  • Hypertension
  • Essential Hypertension
  • Resistant Hypertension

Interventions

DRUG

chlorthalidone

chlorthalidone 25mg/d vs. chlorthalidone 50mg/d

BEHAVIORAL

motivational intervention for non-compliant individuals

motivational interview(s) vs. repeated calls vs. no particular intervention

DRUG

standardized anti-hypertensive treatment

olmesartan, amlodipine, chlorthalidone, +- spironolactone

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Antoinette PECHERE, MD · Geneva University Hospitals, Switzerland

  • Georg B EHRET, MD · Geneva University Hospitals, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2017-05-31
Completion
2017-05-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01083017 on ClinicalTrials.gov